Developing Precision-Targeted Therapies Against Cancer
Through technology, passion and determination, Rakuten Medical is pioneering the development of new approaches to treat cancer.
We are a privately funded, global biotechnology company with offices in the U.S., Japan, Taiwan, the Netherlands and Germany. We aim to become a leader in precision-targeted therapies through our proprietary, anti-cancer treatment platform, Rakuten Medical's Illuminox™.
Rakuten Medical's Illuminox is being studied to determine if it acts broadly across different tumor types and patient populations by potentially inducing tumor necrosis with minimal effects on normal tissue while triggering an immune response for enhanced anti-cancer activity throughout the body.
Rakuten Medical’s lead program, ASP-1929, has achieved Fast Track designation from both the FDA and the Japanese Ministry of Health, Labour and Welfare, and it is in Phase 3 clinical trials for recurrent head and neck squamous cell carcinoma (rHNSCC). The Phase 2 study results on this investigational therapy suggest a high response rate in patients who have failed existing treatment options and have the potential to improve progression-free and overall survival.
Additional Phase 2 studies for ASP-1929 are also underway to evaluate the safety and efficacy in patients with other cancer types.
"We are for the cancer patients, to offer them the possibility to battle cancer, with precision-targeted medicines
We create a new way to fight cancer, with uncompromising science, passion and commitment.
Rakuten Medical pursues a future where cancer
is no longer a threat to the patients' lives."*
*ASP-1929 is an experimental therapy and has not been approved by the FDA
Chairman of the Board & CEO
Miguel Garcia-Guzman, Ph.D.
Vice Chairman & CSO
Merrill Biel, M.D., PH.D., F.A.C.S.
Chief Medical Officer
Takashi Toraishi, Ph.D.
President and COO
Carlos Garcia, M.S.
Chief Technology Officer
Director of the Board
Andreas Rose, Dipl.-Ing.
President and Managing Director, Rakuten Medical Europe GmbH
Maria Tello, M.D.
Executive Director of Safety & Pharmacovigilance
Shawn Schaffer, PH.D.
Head of Quality
Agatha Martindale, C.P.A.
Suzane San, M.B.A.
Head of People Operations
Gabriela Velasquez, B.A.
Leader, Talent Acquisition & Development
Abhijit Bhatia, M.S., M.B.A.
Director, Corporate & Business Development
Director of Strategic Planning and Operations, Head of Asia Business Promotion, Rakuten Medical Japan, K.K.
Lola Fong, M.B.A.
Sr. Director of Global Clinical Operations
Takuji Achiwa, M.S.
VP Clinical Development, Rakuten Medical Japan K.K.
Sampsa Kuusiluoma, MSE, CLSSGB.
Manager of Operations, Quality & Regulatory Affairs, Rakuten Medical Europe GmbH
Eileen Sun, Ph.D
Associate Director, Leader of Program Management
Jessica Berrett, M.H.A.
Director of Data Management
Code of Business Conduct
Rakuten Medical’s Code of Business Conduct provides guidelines to our directors, officers, employees, and our agents, consultants, and contractors to conduct our business ethically and in strict compliance with all applicable laws, rules, and regulations.
At Rakuten Medical, it’s everyone’s responsibility to follow the Code of Business Conduct and comply not only with the word of these policy, but also with its essence and intent. Everyone at Rakuten Medical must:
- Understand and adhere to the Code of Business Conduct.
- Follow all applicable laws and regulations.
- Follow all Rakuten Medical policies.
- Seek clarification or guidance when they have a question about the Code of Business Conduct or compliance.
- Report a concern when they suspect a violation of the Code of Business Conduct.
- Use their good judgment and always act with honesty and integrity and ethics.